|
Immune checkpoint inhibitors (ICI) response in metastatic non-small cell lung cancer (NSCLC) patients with WNT pathway mutations (APC/CTNNB1). |
|
|
Consulting or Advisory Role - Boehringer Ingelheim; Bristol-Myers Squibb; Kyowa Hakko Kirin; Merck Sharp & Dohme; MSD Oncology; Roche |
Travel, Accommodations, Expenses - Acraf; Boehringer Ingelheim; Bristol-Myers Squibb; Merck Sharp & Dohme; Pfizer; Roche |
|
|
Consulting or Advisory Role - Boehringer Ingelheim; Kyowa Hakko Kirin; Lilly; MSD Oncology; Roche Pharma AG; Sanofi |
Travel, Accommodations, Expenses - Boehringer Ingelheim; Celgene; Kyowa Hakko Kirin; MSD Oncology; Pfizer; Roche Pharma AG |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Boehringer Ingelheim; Roche |
Research Funding - Merck Serono (Inst) |
Travel, Accommodations, Expenses - Boehringer Ingelheim; MSD Oncology; Pfizer; Roche |
|
|
Consulting or Advisory Role - Boehringer Ingelheim; Bristol-Myers Squibb; Pfizer; Roche |
Expert Testimony - Oryzon Genomics |
Travel, Accommodations, Expenses - Boehringer Ingelheim; Pfizer |
|
|
Consulting or Advisory Role - Boehringer Ingelheim; Bristol-Myers Squibb; Merck Sharp & Dohme; MSD Oncology; Pfizer; Roche |
Speakers' Bureau - Boehringer Ingelheim; Bristol-Myers Squibb; Merck Sharp & Dohme; Pfizer; Roche |
Travel, Accommodations, Expenses - Boehringer Ingelheim; Bristol-Myers Squibb; Merck Sharp & Dohme; Pfizer; Roche |
|
|
Consulting or Advisory Role - Amphera; Boehringer Ingelheim; Bristol-Myers Squibb; MSD Oncology; Pfizer/EMD Serono; Roche |
Travel, Accommodations, Expenses - Boehringer Ingelheim; Pfizer; Roche |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Roche |
Speakers' Bureau - Amgen; Ipsen; MSD Oncology; Roche; Sanofi; SERVIER; Symphogen |
|
|
|
Research Funding - Bayer; BluPrint Oncology; Cellestia Biotech; Merus; Novartis |
|
|
Consulting or Advisory Role - Bayer Health; Guardant Health; Novartis |
|
|
Consulting or Advisory Role - Abbvie; AstraZeneca; BerGenBio; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Guardant Health; Janssen; Lilly; Medscape; Merck KGaA; Merck Sharp & Dohme; Novartis; Pfizer; priME Oncology; Roche; Samsung; Takeda; touchIME |
Speakers' Bureau - AbbVie; Abbvie; AstraZeneca; BerGenBio; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Guardant Health; Janssen; Lilly; medscape; Merck KGaA; Merck Sharp & Dohme; Novartis; Pfizer; Prime Oncology; Roche; Samsung; Takeda; touchIME |
Research Funding - EMD Serono (Inst); Merck (Inst) |
Other Relationship - GRÍFOLS |